This article is more than 5 years old. Information may no longer be current.

Refocus begins phase 2 scleral implant trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DALLAS — The first two patients enrolled in Refocus Group’s scleral implant trial for the treatment of presbyopia have undergone the procedure, according to a press release. Gene Zdenek, MD, of Reseda, Calif., one of five investigators in the United States, implanted the first two patients. A total of 100 patients will undergo the procedure, and results will be compared with 50 control patients.

Earlier this month, Refocus re-assumed the licensing and all worldwide marketing rights to its PresView scleral implant from CIBA Vision. In addition to presbyopia, the implant is in trials for the treatment of glaucoma and ocular hypertension, according to company information.